doi: 10.1186/s40880-015-0047-1

Targeted therapy: resistance and re-sensitization

Dao-Hong Chen and Xiao-Shi Zhang

Biomedical Research Institute, Yiling Pharmaceutical Company, Beijing 102600, P. R. China

[Abstract] The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug-resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re-sensitize cancer cells/tissues therapeutically.

Chinese Journal of Cancer 2015, Volume: 34, Issue 11, Page: 496-501

[ PDF Full-text ]
[Google Scholar]

Cite this article

Dao-Hong Chen and Xiao-Shi Zhang. Targeted therapy: resistance and re-sensitization. Chin J Cancer. 2015, 34(11):496-501. doi:10.1186/s40880-015-0047-1


Export citations

EndNote